Wednesday, August 21, 2019 9:17:26 PM
TLT on Stockhouse is polluted with bashers and shorts.
Why? TLT trades on the lowest regulated markets, the TSXV Canada and the OTC in the US. (TLTFF)
It is a penny stock and has no institutional ownership. Therefore it is a shorters paradise. Scare the crap out of individual holders and watch them panic and sell.
Fantastic biotech but questionable financial direction.
Could have up to 250 million shares outstanding if financing is fully alloted.
Problem with that is still need to achieve a Nasdaq listing before institutional buys.
Need a $4 share price and millions in the bank.
How does a company achieve a $Billion MarketCap on the OTC?
Why? TLT trades on the lowest regulated markets, the TSXV Canada and the OTC in the US. (TLTFF)
It is a penny stock and has no institutional ownership. Therefore it is a shorters paradise. Scare the crap out of individual holders and watch them panic and sell.
Fantastic biotech but questionable financial direction.
Could have up to 250 million shares outstanding if financing is fully alloted.
Problem with that is still need to achieve a Nasdaq listing before institutional buys.
Need a $4 share price and millions in the bank.
How does a company achieve a $Billion MarketCap on the OTC?
Recent TLTFF News
- Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update • Newsfile • 05/04/2026 09:22:00 PM
- Theralase(R) Closes $CAN 2.66 Million Financing • Newsfile • 04/10/2026 11:00:00 AM
- Theralase(R) Closes $1.1 M Non-Brokered Private Placement • Newsfile • 03/10/2026 11:00:00 AM
- Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer • Newsfile • 03/09/2026 11:00:00 AM
- Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress • Newsfile • 02/20/2026 12:00:00 PM
- Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress • Newsfile • 02/17/2026 12:00:00 PM
- Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting • Newsfile • 02/10/2026 12:00:00 PM
- Theralase(R) Provides Update on Bladder Cancer Clinical Study • Newsfile • 02/04/2026 12:00:00 PM
- Theralase and Ferring ink deal for new bladder cancer study • IH Market News • 01/14/2026 11:05:00 AM
- New Bladder Cancer Collaboration Sparks Sharp Rally in This Micro Cap Stock • AllPennyStocks.com • 01/12/2026 03:23:00 PM
- Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer • Newsfile • 01/12/2026 12:00:00 PM
- Theralase(R) Closes $1.3 M Non-Brokered Private Placement • Newsfile • 12/23/2025 09:40:00 PM
- Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing • Newsfile • 12/12/2025 10:00:00 PM
- Theralase(R) Investor Conference Call Reminder • Newsfile • 11/17/2025 12:00:00 PM
- Theralase(R) Releases 3Q2025 Financial Statements • Newsfile • 11/10/2025 12:00:00 PM
- Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus • Newsfile • 09/24/2025 11:00:00 AM
